Bain Capital to Offload 2.4% Stake in Emcure Pharmaceuticals for ₹551 Crore

1 min read     Updated on 04 Jul 2025, 12:35 AM
scanxBy ScanX News Team
whatsapptwittershare
Overview

BC Investments IV, backed by Bain Capital, plans to sell 2.4% (45.5 lakh shares) of Emcure Pharmaceuticals for ₹551 crore. The offer price is ₹1,225 per share, a 4% discount to the current market price. The block deal, to be executed through Kotak Securities, comes after Emcure reported strong Q4 results with a 63% increase in profit after tax to ₹197 crore and a 19.5% rise in revenue to ₹2,116 crore.

13115115

*this image is generated using AI for illustrative purposes only.

Emcure Pharmaceuticals is set to see a change in its shareholding as Bain Capital-backed BC Investments IV plans to reduce its stake through a significant block deal, according to recent market reports. The private equity firm intends to sell approximately 2.4% of its holdings in the pharmaceutical company, aiming to raise ₹551 crore.

Block Deal Details

Aspect Detail
Stake for Sale 2.4% (45.5 lakh shares)
Total Offer Size ₹551.00 crore
Floor Price ₹1,279.80 per share
Offer Price ₹1,225.00 per share
Discount 4% to the current market price
Execution Date Friday (upcoming)
Book Runner Kotak Securities

The offer price of ₹1,225.00 per share represents a 4% discount to Emcure Pharmaceuticals' current market price, potentially making it an attractive proposition for institutional investors looking to acquire a substantial stake in the company.

Recent Financial Performance

Emcure Pharmaceuticals has recently reported strong financial results for the fourth quarter:

Metric Result
Q4 Profit After Tax (PAT) ₹197.00 crore, up 63% year-over-year
Q4 Revenue ₹2,116.00 crore, an increase of 19.5% year-over-year

The company's robust financial performance may contribute to investor interest in the upcoming block deal.

Market Impact

This block deal represents a significant movement of shares and could potentially impact Emcure Pharmaceuticals' stock price in the short term. Investors and market analysts will be closely watching the execution of this transaction and its effect on the company's shareholding pattern.

The successful completion of this block deal would mark a partial exit for Bain Capital from its investment in Emcure Pharmaceuticals, potentially signaling a shift in the company's ownership structure.

As the pharmaceutical sector continues to be a focus of investor interest, particularly in the wake of global health challenges, this transaction may also reflect broader trends in private equity strategies within the healthcare and life sciences industries.

Historical Stock Returns for Emcure Pharmaceuticals

1 Day5 Days1 Month6 Months1 Year5 Years
+1.33%+0.18%+10.35%+17.08%+9.67%+5.04%
Emcure Pharmaceuticals
View in Depthredirect
like15
dislike

Emcure Pharmaceuticals to Acquire Remaining Stake in Zuventus Healthcare for ₹724.9 Crore

1 min read     Updated on 21 Jun 2025, 08:00 PM
scanxBy ScanX News Team
whatsapptwittershare
Overview

Emcure Pharmaceuticals announced plans to acquire the remaining 20.42% stake in Zuventus Healthcare Ltd for ₹724.90 crore. This acquisition will make Zuventus Healthcare a wholly owned subsidiary of Emcure. The transaction is expected to close in Q2 FY26, marking a significant move to strengthen Emcure's market position in the Indian pharmaceutical industry.

12061849

*this image is generated using AI for illustrative purposes only.

Emcure Pharmaceuticals , a prominent player in the Indian pharmaceutical industry, has announced a significant move to strengthen its market position. The company is set to acquire the remaining 20.42% stake in Zuventus Healthcare Ltd, a transaction valued at ₹724.90 crore.

Key Highlights

  • Acquisition Details: Emcure Pharmaceuticals will purchase the remaining 20.42% stake in Zuventus Healthcare Ltd.
  • Transaction Value: The deal is valued at ₹724.90 crore.
  • Outcome: Upon completion, Zuventus Healthcare will become a wholly owned subsidiary of Emcure Pharmaceuticals.
  • Expected Closure: The transaction is anticipated to close in Q2 FY26.

Strategic Implications

This acquisition marks a strategic move for Emcure Pharmaceuticals, consolidating its ownership in Zuventus Healthcare. By acquiring the remaining stake, Emcure aims to strengthen its portfolio and potentially enhance its market presence in the healthcare sector.

Financial Considerations

The ₹724.90 crore investment demonstrates Emcure's commitment to expanding its footprint in the pharmaceutical industry. This substantial financial commitment suggests that the company sees significant value in fully integrating Zuventus Healthcare into its operations.

Looking Ahead

While the deal's closure is projected for Q2 FY26, this timeline allows both companies ample opportunity to plan for a smooth transition and integration. Stakeholders will be keen to observe how this acquisition impacts Emcure's overall business strategy and financial performance in the coming years.

As this development unfolds, industry watchers will be monitoring how Emcure Pharmaceuticals leverages this acquisition to drive growth and enhance its competitive position in the pharmaceutical market.

Historical Stock Returns for Emcure Pharmaceuticals

1 Day5 Days1 Month6 Months1 Year5 Years
+1.33%+0.18%+10.35%+17.08%+9.67%+5.04%
Emcure Pharmaceuticals
View in Depthredirect
like18
dislike
More News on Emcure Pharmaceuticals
Explore Other Articles
Praxis Home Retail Announces Rights Issue Schedule for August 2025 1 hour ago
Alldigi Tech Revamps Business Segments, Reports Q1 FY26 Results, Declares INR 30 Interim Dividend 2 hours ago
Indus Infra Trust Reports Q1 Results: Distribution of Rs. 3.25 Per Unit Declared 2 hours ago
Premier Explosives Secures ₹22.36 Crore International Order for Rocket Motors 2 hours ago
Orchid Pharma Secures Global Rights to Enmetazobactam Through Strategic Asset Acquisitions 3 hours ago
1,427.70
+18.80
(+1.33%)